Loxo Oncology (LOXO) Given Coverage Optimism Rating of 0.12
Media coverage about Loxo Oncology (NASDAQ:LOXO) has trended somewhat positive recently, Accern reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Loxo Oncology earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 44.5689371296483 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the headlines that may have effected Accern’s scoring:
- Loxo Oncology, Inc. (LOXO) Receives Consensus Rating of “Buy” from Brokerages (americanbankingnews.com)
- Analyst Recommendations for Ignyta and Its Peers in January 2018 (finance.yahoo.com)
- A Close Look at Ignyta’s Licensing Agreement (finance.yahoo.com)
- Loxo Oncology (LOXO) Rating Increased to Hold at Zacks Investment Research (americanbankingnews.com)
Loxo Oncology (NASDAQ:LOXO) opened at $89.99 on Friday. Loxo Oncology has a 12 month low of $36.75 and a 12 month high of $95.92. The firm has a market capitalization of $2,660.25, a P/E ratio of -15.44 and a beta of 2.54.
A number of equities analysts have recently weighed in on the company. Zacks Investment Research upgraded Loxo Oncology from a “sell” rating to a “hold” rating in a research note on Tuesday, January 9th. BTIG Research restated a “buy” rating and issued a $102.00 target price (up previously from $75.00) on shares of Loxo Oncology in a research note on Friday, September 29th. Cowen restated a “buy” rating on shares of Loxo Oncology in a research note on Thursday, September 28th. BidaskClub upgraded Loxo Oncology from a “sell” rating to a “hold” rating in a research note on Friday, December 22nd. Finally, Citigroup restated a “buy” rating and issued a $112.00 target price (up previously from $86.00) on shares of Loxo Oncology in a research note on Friday, October 20th. Two investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. Loxo Oncology currently has an average rating of “Buy” and an average target price of $90.57.
In related news, Director Orbimed Advisors Llc sold 270,000 shares of Loxo Oncology stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $74.26, for a total value of $20,050,200.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Aisling Capital Iii Lp sold 500,000 shares of Loxo Oncology stock in a transaction that occurred on Wednesday, November 22nd. The stock was sold at an average price of $75.00, for a total transaction of $37,500,000.00. The disclosure for this sale can be found here. Insiders sold a total of 1,614,555 shares of company stock worth $124,567,942 in the last 90 days. Company insiders own 44.40% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece of content was first published by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2018/01/14/loxo-oncology-loxo-given-coverage-optimism-rating-of-0-12.html.
About Loxo Oncology
Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.
Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.